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a model in which both aystemic arterial and IC bFGF effectively promote
coronary collateral growth, 1PbFGF was not efficacious. A key difference
between parenterel and 1Padministration is directional (delivery via the vas-
cular lumen vs. abiuminal delivery). This factor may be responsible for the
lack of effect of 1PbFGF in this study.
-1 C-~pNatri.reti. PeptideMediatescGMP
Generation and Antimitogenic Actiona in Human
Coronary Vaacular Smooth Muscle Cells
J. Schirger, J.C. Burnett, Jr., C.-M. Wei. Mayo Clinic, Rochestec MN, USA
C-type natriuretic peptide (CNP) is an endothelial cell derived cardiovascular
peptide which mediates vasodilato!y and antimitogenic aclions. Previous
studies demonstrate that the biological actions of CNP are mediated through
the activation of a particulate guanylyl cyclase receptor and cGMP. To date,
it remains unclear as to the abilify of CNP to stimulate cGMP generation
and to inhibit proliferation in human coronay vaacular smooth muscle cells
(HCVSMCS). Therefore, the preaent studies were designed to determine
1) the effects of CNP upon cGMP generation in HCVSMCS and 2) the
antimitogenic actions of CNP upon endothelin-1 (ET-1)mediated proliferation
in HCVSMCS. We hypothesized that CNP increases cGMP generation in
HCVSMCS and inhibits the proliferative effect of ET-1 in HCVSMCS. To
test this hypothesis we determined cGMP by radioimmunoassay in cultured
HCVSMCSin the presence and absence of CNP.Additionally, cultured cells
were stimulated by ET-1 (1OL7M)in the presence and absence of CNP
(10-7M) and thymidine incorporation was determined.
cGMP (omol/ml) 2 hours 8 hours 24 hours
.. ,
Control 0.50l 0.10 0.45+ 0,05 0.65+ 0.15
CNP(10-7M) 0.95l 0.55 1.35i 0.45 2.80+ 1.00
ET-1 increased thymidine incorporation in HCVSMCS as compared to
.unstimulated cells (1362 & 288 vs 190 * 24 cptiwell, p < 0.05) and CNP
inhibited ET-1 mediate thymidine incorporation (298 l 51 vs 1362 + 288
cpm/well, p < 0.05). These studies supporl the concept that CNP is an im-
porlant activator of cGMP accumulation in human coronary vascular smooth
muscle cells and plays an important autocrine and paracrine role as an
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Clinic, Rochestefi MN, USA
Beeic fibroblaat growth factor (bFGF) is a vasodilator which is dependent
on the endothelium-derived relaxing factor (EDRF) pathway. Hypercholes-
teroiemia (HC) is characterized by decreased corona~ EDRF activity. Thus,
we examined whether the reduced EDRF activity associated with HC results
in coronaty vasoconstriotion in response to bFGF. Intracoronary bFGF (0.02
@kg/rein) was infused at baseline and after 10 weeks of high-cholesterol
diet. In addition, L-NG-momo-methyl-arginine (L-NMMA), a nitric oxide syn-
theee inhibitor, was infused intracoronary at baseline 5 (r@kg/min) with and
without bFGF. Percent change in coronaw artew diameter (%ACAD) and
coronary blood flow (%ACBF) were calculated based on coronaty quantita-
tive angiography and Doppler: *P <0.05 vs. baseline, ‘p -=0.05 vs LNMMA
and baseline bFGF.
bFGF(n= 5) bFGF(n= 5) LNMMA LNMMA+ bFGF
Saseline 10 wks, HC (n= 4) (n= 7)
%ACAD 12&5 -14 +6* –21 * 4 –75 i lzt
%ACBF 33*33 –45 *6* 45* 5 –89+9t
Conclusions: BFGF is a mild coronay vasodilator in the steady-state.
However,endogenous (HC) and exogenous (by L-NMMA) inhibition of EDRF
activity resulted in coronaty vasoeonstrietion in response to bFGF. These
studies auggeat that the coronary vasomotor effects of bFGF are regulated
by the status of the EDRF pathway.
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Secretion of Brain Natriuretic Peptide in Cultured
. .Human Coronary Vascular Smooth Muscle Cells:
A New Autocrine and Paracrine Role for the
Natriuretic Peptide System
C.-M. Wei, D.M, Heublein, J.C. Burnett, Jr,, Cardiorerra/Research
Laboratory Mayo Clinic, Rocheste< MN, USA
Brain natriuretic peptide (BNP) is a peptide of cardiac origin which regulates
plasma volume and also vascular tone and growth. Recently, we have re-
ported that BNP is a potent inhibitor of endothelin-1 mediated proliferation
in human coronary vascular smooth muscle cells (HCOVSMC).While BNP
has been reported to be produced and released from atrial and ventricular
myocardium, we investigated the hypothesis that BNP may be present and
secreted from human coronary vascular smooth muscle cells. Therefore, the
present study was designed to investigate the secretion of BNP in cultured
human coronary vascular smooth muscle cells (HCOVSMC:Clonetics, San
Diego, CA). BNP and its second messenger cGMP in culture media were
determined by radioimmunoassay.The presence of BNP was determined by
immunohistochemical staining using ahuman BNP polyclonal antibody. BNP
immunoreacfivity was significantly increased in culture media after 46 hours
incubation compared with baseline (323 + 85 vs 11 + 4 pg/ml, p < 0.05).
Cyclic GMP immunoreactivity also increased in coronary vascular smooth
muscle cells after culture (0.4 * 0.03 vs 0.05 + 0.01 pmol/min, p < 0.05), To
confirm the presence of BNP and cGMP in HCOVSMC,two stage immuno-
histochemieel staining was petformed, In these studies, BNP and c’GMP
stained positively in cytoplasm of HCOVSMCwhile non-immune staining was
negative, The current study demonstrates that BNP is secreted by cultured
HCOVSMC in association with an increase in cGMP accumulation. These
date suggest a probable autocrine and paracrine role for BNP as a peptide
of coronary vascular smooth muscle origin which may participate in corona~
vascular smooth muscle regulation.
m961 120 Effect of 17&Estradiol Treatment on Intimal
Apoptoais and Cell Proliferation in an
Experimental Atheroscleroaia Model
J, Kamenz,H.Hanke,S. Hanke,C. Lenz, H. Kahn, V. Hombach. University
of U/m Medical Centec Div. of Cardio/ogN U/m, Germany
It has been shown that administration of 17& Estradiol does reduce intimal
thickening in experimental atherosclerosis. So far the mechanism of the
atheroprotective effect of estrogen is not well understood. Aim of the present
study was to determine the effect of estrogen on intimal apoptosis in compar-
ison to cellular proliferation during plaque development in an experimental
atherosclerosis model, Thirty female New-Zealand rabbits’were included in
this study. Six rabbits served as a control group without cholesterol feeding
(CHOL) or hormone treatment, Twenty-four rabbits received a 0,5% CHOL
diet for 12 weeks and were separated in 3 different groups:
Group A only CHOL, Group B CHOL + ovareetomy, Group C CHOL +
ovarectomy + 17fJ-Estradiol1 mg/kg BW/week for 12 weeks, The aortic arch
was then histologically and morphometrically analyzed. For in-situ detection
of apoptosis the TUNEL-technique (TdT-mediatad dUTP nick end labeling)
was used. Bromodeoxyuridine-labeling allowed the determination of cells
undergoing DNA-synthesis. Resu/ts:
Studygroup Intimalarea(mm2) Apoptoiiccetls/mm2 Proliferatingcella/mm2
Controln = 6 <0.1 0 0
GroupA n= 6 4.5+ 2.8 4,4i 1.7 46.7 + 16.3
GrOUD B n = 8 4,s + 1,7 3.7 * 1.5 45,6 + 11,9
GroupC n = 6 1.4 * 0.9(p< 0,05) 6.1 + 4,3 21.6 + 22.6 (p < 0,05)
In summary,continuous estrogen treatment during atherosclerotic plaque
development seems to reduce intimal cell proliferation and to have no influ-
ence on the apoptosis rate in the intima, resulting in a significantly smaller
intimal area.
1961-121 I AssociatiOnofTransformingGrowthFector-bet8
Isoforms with Coronary Plaque in Patienta with
Coronary Ischemia
H. Ueda, M. Imazur K. Sumii, H. Yamamoto, K. One, F.Tadehara,
Y. Hayashi, W, Yaeui, M. Yamakido. Hiroshima Univeraify Schoo/ of
Medicine, Hiroshima, Japan
Transforming growth factor (TGF) $sare important cyfokines in the vascular
system. But an association between their expression in coronary Ieaionsand
clinical pathophysiology has not been fully elucidated. We studied speei-
mens of coronary lesions obtained at directional coronary atherectomy in 59
patients with the following diagnoses: stable angina (SA, n = 8), acute coro-
nary syndromes (ACS, n = 21), or restenosis (RS, n = 30). The specimens
